Clinical trials / Depression
Recruiting psychedelic and ketamine trials for depression
86 trials registered on ClinicalTrials.gov were recruiting on 26 Oct 2026, 49 of them at sites in the United States (24 states). By substance: Ketamine / esketamine 49, Psilocybin 33, DMT / ayahuasca 3, LSD 1.
What the published research shows so far: Psilocybin for depression: what the research shows; Ketamine and esketamine (Spravato) for depression
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Trials with US sites
Phase 3Ketamine / esketamineNCT07227454
A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder (AVENUE)
- Conditions:
- Depressive Disorder, Major
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 12 Years to 17 Years, 258 participants planned
- Also in:
- Brazil, Hungary, Italy, Romania, Spain, Taiwan
- University of Alabama at Birmingham, Birmingham, Alabama
- Children's National Medical Center, Washington D.C., District of Columbia
- Peachford Hospital-Atlanta Behavioral Research, Atlanta, Georgia
- Endeavor Health Evanston Hospital, Evanston, Illinois
- Johns Hopkins University, Baltimore, Maryland
- Boston Childrens Hospital, Boston, Massachusetts
- and 4 more US sites on the registry record
Phase 3Ketamine / esketamineNCT07716098
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Conditions:
- Depressive Disorder, Treatment-Resistant
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 18 Years and over, 348 participants planned
- Also in:
- Japan, Taiwan
- Anderson Clinical Research, Redlands, California
- Artemis Institute for Clinical Research, San Diego, California
- Psych Atlanta, P.C., Marietta, Georgia
- Psychiatric Medicine Associates LLC, Skokie, Illinois
- Neurobehavioral Research Inc, Cedarhurst, New York
- The Medical Research Network, LLC, New York, New York
- and 1 more US site on the registry record
Phase 3Ketamine / esketamineNCT06713616
PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
- Conditions:
- Depression
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 400 participants planned
- Mood Institute, Milford, Connecticut
- Yale School of Medicine, New Haven, Connecticut
- Emory University, Atlanta, Georgia
- Athena Care, Nashville, Tennessee
- Houston Center for Advanced Psychiatric Treatment, Bellaire, Texas
- Seattle NTC, Seattle, Washington
ObservationalKetamine / esketamineNCT06725277
The OBSERVE Protocol
- Conditions:
- Major Depression Disorder
- Sponsor:
- Yale University
- Who:
- 450 participants planned
- Mood Institute, Milford, Connecticut
- Yale School of Medicine, New Haven, Connecticut
- Emory University, Atlanta, Georgia
- Athena Care, Nashville, Tennessee
- Houston Center for Advanced Psychiatric Treatment, Bellaire, Texas
- Seattle NTC, Seattle, Washington
Phase 3PsilocybinNCT07226232
Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression (PIVOT)
- Conditions:
- Major Depression
- Sponsor:
- VA Office of Research and Development
- Who:
- ages 18 Years to 75 Years, 240 participants planned
- Birmingham VA Medical Center, Birmingham, AL, Birmingham, Alabama
- Tuscaloosa VA Medical Center, Tuscaloosa, AL, Tuscaloosa, Alabama
- VA Portland Health Care System, Portland, OR, Portland, Oregon
- Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, Philadelphia, Pennsylvania
- VA Puget Sound Health Care System Seattle Division, Seattle, WA, Seattle, Washington
ObservationalKetamine / esketamineNCT06070766
RIVER At Home Ketamine Protocols
- Conditions:
- Chronic Condition; Chronic Pain; Chronic Disease; Major Depressive Disorder; Post Traumatic Stress Disorder; Anxiety Disorders
- Sponsor:
- RIVER Foundation
- Who:
- ages 18 Years and over, 50000 participants planned
- RIVER Foundation, Bigfork, Montana
- RIVER Telehealth, Helena, Montana
Phase 1Ketamine / esketamineNCT06085937
Feasibility and Safety of Ketamine for Suicidal Patients in the Emergency Department
- Conditions:
- Suicide; Suicidal Ideation; Depression
- Sponsor:
- Lindsay Maguire, MD
- Who:
- ages 18 Years to 65 Years, 50 participants planned
- University of Kansas Strawberry Hill Campus, Kansas City, Kansas (not yet recruiting)
- University of Kansas Medical Center Emergency Department, Kansas City, Kansas
Phase 1Ketamine / esketamineNCT06480201
Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression
- Conditions:
- Healthy; Major Depressive Disorder; Treatment Resistant Depression
- Sponsor:
- Texas A&M University
- Who:
- ages 21 Years to 45 Years, 100 participants planned, accepts healthy volunteers
Phase 4Ketamine / esketamineNCT06903819
Ketamine for Pain, Opioid Use, and Mental Health in Orthopedic Trauma Patients
- Conditions:
- Orthopedic Trauma Surgery Patients; Postoperative Pain; Opioid Use; Depression; Post-traumatic Stress Disorder (PTSD)
- Sponsor:
- Texas Tech University Health Sciences Center
- Who:
- ages 18 Years to 65 Years, 90 participants planned
Phase 2Ketamine / esketamineNCT02122562
Ketamine Alcohol (in Treatment-Resistant Depression)
- Conditions:
- Magnetic Resonance Imaging; Major Depression; Alcoholism
- Sponsor:
- Mark Niciu
- Who:
- ages 18 Years to 55 Years, 60 participants planned
- University of Iowa Health Care, Iowa City, Iowa
Phase 2Ketamine / esketamineNCT02543983
Neurobiology of Suicide
- Conditions:
- Healthy Volunteers; Depression
- Sponsor:
- National Institute of Mental Health (NIMH)
- Who:
- ages 18 Years to 70 Years, 325 participants planned, accepts healthy volunteers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Phase 1Ketamine / esketamineNCT03065335
Neuropharmacologic Imaging and Biomarker Assessments of Response to Acute and Repeated-Dosed Ketamine Infusions in Major Depressive Disorder
- Conditions:
- Healthy Volunteer; Major Depressive Disorder; Depression
- Sponsor:
- National Institute of Mental Health (NIMH)
- Who:
- ages 18 Years to 65 Years, 150 participants planned, accepts healthy volunteers
- National Institutes of Health Clinical Center, Bethesda, Maryland
Early phase 1PsilocybinNCT04123314
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
- Conditions:
- Depressive Symptoms; Depression; Alzheimer Disease; Mild Cognitive Impairment
- Sponsor:
- Johns Hopkins University
- Who:
- ages 18 Years to 85 Years, 20 participants planned
- Johns Hopkins Center for Psychedelic and Consciousness Research, Baltimore, Maryland
ObservationalKetamine / esketamineNCT04480918
University of Iowa Interventional Psychiatry Service Patient Registry
- Conditions:
- Treatment Resistant Depression; Major Depressive Episode; Major Depression; Major Depressive Disorder; Bipolar Disorder; Bipolar Depression; Obsessive-Compulsive Disorder
- Sponsor:
- Mark Niciu
- Who:
- ages 18 Years to 99 Years, 1000 participants planned
- University of Iowa Health Care, Iowa City, Iowa
Early phase 1Ketamine / esketamineNCT05327699
Glutamatergic Adaptation to Stress as a Mechanism for Anhedonia and Treatment Response With Ketamine
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Emory University
- Who:
- ages 18 Years to 65 Years, 140 participants planned, accepts healthy volunteers
- Emory University, Atlanta, Georgia
Phase 4Ketamine / esketamineNCT05450432
Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Massachusetts General Hospital
- Who:
- ages 18 Years to 70 Years, 100 participants planned
- Massachusetts General Hospital, Boston, Massachusetts
Phase 2Ketamine / esketamineNCT05786066
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
- Conditions:
- Depressive Disorder; Major Depressive Disorder; Bipolar Disorder; Post Traumatic Stress Disorder; Suicidal Ideation
- Sponsor:
- Yale University
- Who:
- ages 21 Years to 65 Years, 30 participants planned
- VA Connecticut Healthcare System, West Haven, Connecticut
Phase 1Ketamine / esketamineNCT05915013
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
- Conditions:
- Depressive Disorder, Major; Post Traumatic Stress Disorder
- Sponsor:
- Yale University
- Who:
- ages 18 Years to 60 Years, 50 participants planned
- Yale University, New Haven, Connecticut
ObservationalKetamine / esketamineNCT06038409
Ketamine Treatment Plans for Chronic Conditions
- Conditions:
- Chronic Pain; Depressive Disorder; Anxiety Disorders; Chronic Disease
- Sponsor:
- RIVER Foundation
- Who:
- ages 18 Years and over, 500 participants planned
- RIVER Telehealth, Helena, Montana
Phase 2PsilocybinNCT06132178
Psilocybin rTMS for Treatment Resistant Depression (PSILOBSD)
- Conditions:
- Treatment Resistant Depression; MDD; Major Depressive Disorder; Recurrent Depression; Depression
- Sponsor:
- University of Texas at Austin
- Who:
- ages 22 Years to 65 Years, 100 participants planned
- Health Discovery Building (HDB), 1601 Trinity St., Bldg B., Z0600, Austin, Texas
Phase 2PsilocybinNCT06200155
Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy
- Conditions:
- Depression, Anxiety; Psilocybin-Assisted Psychotherapy; Advanced Cancer
- Sponsor:
- M.D. Anderson Cancer Center
- Who:
- ages 25 Years and over, 48 participants planned
- MD Anderson Cancer Center, Houston, Texas
Phase 4Ketamine / esketamineNCT06213324
Neural Circuit Effects of Ketamine in Depression
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 18 Years to 65 Years, 120 participants planned, accepts healthy volunteers
- Icahn School of Medicine at Mount Sinai, New York, New York
Phase 3PsilocybinNCT06247839
The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Sharmin Ghaznavi
- Who:
- ages 18 Years to 55 Years, 20 participants planned
- Athinoula A. Martinos Center for Biomedical Imaging, Charlestown, Massachusetts
Phase 1PsilocybinNCT06355414
Psilocybin in Chronic Low Back Pain and Depression
- Conditions:
- Chronic Low-back Pain; Depression
- Sponsor:
- Johns Hopkins University
- Who:
- ages 21 Years to 80 Years, 40 participants planned
- Johns Hopkins University School of Medicine, Baltimore, Maryland
Phase 2Ketamine / esketamineNCT06402955
Imaging Depression in Parkinson's Disease
- Conditions:
- Parkinson's Disease; Major Depressive Disorder
- Sponsor:
- Yale University
- Who:
- ages 40 Years to 80 Years, 120 participants planned, accepts healthy volunteers
- Yale University, New Haven, Connecticut
Phase 2Ketamine / esketamineNCT06419439
Ketamine-assisted Integrative Treatment for Veterans With Chronic Low Back Pain and Comorbid Depression
- Conditions:
- Chronic Low Back Pain; Depression
- Sponsor:
- VA Office of Research and Development
- Who:
- ages 18 Years and over, 44 participants planned
- VA Ann Arbor Healthcare System, Ann Arbor, MI, Ann Arbor, Michigan
Phase 1PsilocybinNCT06442423
Open-Label Psilocybin Study in Transdiagnostic Population
- Conditions:
- Transdiagnostic; Depression - Major Depressive Disorder; Anxiety; PTSD Symptoms; PTSD; Substance Use; Substance Use Disorder (SUD); OCD
- Sponsor:
- Yale University
- Who:
- ages 18 Years and over, 50 participants planned, accepts healthy volunteers
- Connecticut Mental Health Center - Yale School of Medicine, New Haven, Connecticut
Phase 2PsilocybinNCT06455293
Psilocybin Therapy for Depression in Parkinson's Disease (PDP2)
- Conditions:
- Parkinson Disease; Depression
- Sponsor:
- Joshua Woolley, MD, PhD
- Who:
- ages 40 Years to 80 Years, 60 participants planned
- University of California, San Francisco, San Francisco, California
Phase 2Ketamine / esketamineNCT06511908
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
- Conditions:
- Suicide; Depressive Disorder, Treatment-Resistant; Ketamine; Molecular Mechanisms of Pharmacological Action; Neurotransmitter Agents; Excitatory Amino Acid Agents; Physiological Effects of Drugs; Depressive Disorder, Major; Depressive Disorder; Depression; Mental Disorders; Mood Disorders; Behavioral Symptoms
- Sponsor:
- National Institute of Mental Health (NIMH)
- Who:
- ages 18 Years to 70 Years, 50 participants planned
- National Institutes of Health Clinical Center, Bethesda, Maryland
Phase 2PsilocybinNCT06512194
Investigation to Understand and Optimize Psilocybin (OPTIMIZE)
- Conditions:
- Depression
- Sponsor:
- Charles Raison
- Who:
- ages 18 Years to 70 Years, 141 participants planned
- Vail Health Behavioral Health, Edwards, Colorado
Phase 2Ketamine / esketamineNCT06559826
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression (KAP)
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 18 Years to 90 Years, 70 participants planned
- Icahn School of Medicine at Mount Sinai, New York, New York
Phase 2PsilocybinNCT06592833
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 21 Years to 80 Years, 60 participants planned
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York
Phase 1/2Ketamine / esketamineNCT06597695
A Ketamine-assisted Group Therapy Intervention for Spanish-speaking Adults With Depression
- Conditions:
- Depression
- Sponsor:
- Juliana Zambrano, MD, MPH
- Who:
- ages 18 Years to 64 Years, 10 participants planned
- Massachusetts General Hospital, Chelsea, Chelsea, Massachusetts
Phase 2Ketamine / esketamineNCT06668571
Intravenous Ketamine for Treatment-Resistant Depression (G2K)
- Conditions:
- Depressive Disorder, Treatment-Resistant; Treatment Resistant Depression (TRD)
- Sponsor:
- Mayo Clinic
- Who:
- ages 18 Years to 65 Years, 30 participants planned
- Mayo Clinic in Rochester, Rochester, Minnesota
Phase 1DMT / ayahuascaNCT06671977
Study of the Safety, Tolerability, Electrophysiological Effects and Efficacy of DMT in Humans (DMT-Bolus)
- Conditions:
- Major Depression Disorder; Depression
- Sponsor:
- Deepak C. D'Souza
- Who:
- ages 21 Years to 65 Years, 60 participants planned, accepts healthy volunteers
- Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine,, West Haven, Connecticut
Phase 2PsilocybinNCT06706232
Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality
- Conditions:
- Bipolar II Disorder; Depression, Bipolar; Suicidality
- Sponsor:
- The University of Texas Health Science Center, Houston
- Who:
- ages 25 Years to 70 Years, 10 participants planned
- The University of Texas Health Science Center at Houston, Houston, Texas
Phase 3Ketamine / esketamineNCT06752759
Nebulized Ketamine for the Treatment of Major Depressive Disorder
- Conditions:
- Severe Depression; Moderate Depression; Ketamine; Midazolam; Peripheral Nervous System Agents; Central Nervous System Agents; Neurotransmitter Agents; Physiologic Effects of Drugs; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Depressive Symptom; Hypnotics and Sedatives; Anti-anxiety Agents; Tranquilizing Agents; Psychotropic Drugs; Anesthetics Agent
- Sponsor:
- Theresa Jacob, PhD, MPH
- Who:
- ages 18 Years to 88 Years, 40 participants planned
- Maimonides Medical Center, Brooklyn, New York
Phase 1Ketamine / esketamineNCT06767566
Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PREPARE-2)
- Conditions:
- Pain; Postpartum Depression
- Sponsor:
- University of Utah
- Who:
- ages 18 Years and over, 50 participants planned, accepts healthy volunteers
- University of Utah, Salt Lake City, Utah
Early phase 1Ketamine / esketamineNCT06788249
Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of Ketamine
- Conditions:
- Major Depressive Disorder (MDD)
- Sponsor:
- University of Pennsylvania
- Who:
- ages 25 Years to 65 Years, 10 participants planned
- University of Pennsylvania, Philadelphia, Pennsylvania
Phase 2PsilocybinNCT06801041
TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors
- Conditions:
- Depression; Anxiety; Cancer
- Sponsor:
- M.D. Anderson Cancer Center
- Who:
- ages 18 Years and over, 20 participants planned
- The University of Texas M. D. Anderson Cancer Center, Houston, Texas
Phase 2PsilocybinNCT06899165
Psilocybin-Assisted Therapy for Intergenerational Trauma
- Conditions:
- Psychological Stress; Depression; Anxiety
- Sponsor:
- Rachel Yehuda
- Who:
- ages 18 Years and over, 100 participants planned
- The Parsons Research Center for Psychedelic Healing, New York, New York
ObservationalKetamine / esketamineNCT06997549
Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments
- Conditions:
- Depression; OCD; Anxiety Depression
- Sponsor:
- Neuronetics
- Who:
- ages 5 Years to 100 Years, 12000 participants planned
- Neuronetics, Malvern, Pennsylvania
Phase 2PsilocybinNCT07104916
Mindfulness-based Psilocybin Therapy for PTSD
- Conditions:
- Post Traumatic Stress Disorder; Depression - Major Depressive Disorder
- Sponsor:
- Anthony P King
- Who:
- ages 21 Years to 65 Years, 30 participants planned
- The Ohio State University Medical Center, Columbus, Ohio
Phase 2PsilocybinNCT07216404
Psilocybin-Assisted Therapy for the Treatment of Major Depressive Disorder in Patients With Non-Small Cell Lung Cancer
- Conditions:
- Lung Non-Small Cell Carcinoma; Unipolar Depression
- Sponsor:
- Alan Davis
- Who:
- ages 18 Years and over, 10 participants planned
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Phase 1/2PsilocybinNCT07251491
Psilocybin to Treat Depression in Spinal Cord Injury (STOP)
- Conditions:
- Spinal Cord Injury; Depression - Major Depressive Disorder; Veteran
- Sponsor:
- James J. Peters Veterans Affairs Medical Center
- Who:
- ages 22 Years and over, 30 participants planned
- James J. Peters Department of Veterans Affairs Medical Center, The Bronx, New York
Phase 1/2PsilocybinNCT07281352
RCT of Psilocybin-assisted CBT for Depression
- Conditions:
- Major Depressive Diorder
- Sponsor:
- University of California, Los Angeles
- Who:
- ages 21 Years to 60 Years, 50 participants planned
- UCLA Semel Institute, Los Angeles, California
Phase 2PsilocybinNCT07610369
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease (PSI-PD)
- Conditions:
- Depression; Parkinson's Disease (PD)
- Sponsor:
- Yale University
- Who:
- ages 40 Years to 80 Years, 40 participants planned
- Yale University, New Haven, Connecticut
Phase 2Ketamine / esketamineNCT07639359
Subanesthetic Ketamine Infusions for Depressive Symptoms in Intensive Care Unit Patients (KID-ICU)
- Conditions:
- Critical Illness; Depressive Symptoms
- Sponsor:
- Hospital Italiano de Buenos Aires
- Who:
- ages 18 Years to 99 Years, 50 participants planned
- Also in:
- Argentina
- Mayo Clinic, Jacksonville, Florida
Phase 4Ketamine / esketamineNCT07680140
Biomarker-Guided Antidepressant Selection (BioSelect)
- Conditions:
- Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD); rTMS; Ketamine; fMRI
- Sponsor:
- Weill Medical College of Cornell University
- Who:
- ages 18 Years to 70 Years, 27 participants planned
- Weill Cornell Medicine, New York, New York
Trials outside the United States
Phase 4Ketamine / esketamineNCT03272698
ECT with Ketamine Anesthesia Vs High Intensity Ketamine with ECT Rescue for Treatment-Resistant Depression
- Conditions:
- Treatment Resistant Depression; Ketamine
- Sponsor:
- University of Saskatchewan
- Who:
- ages 18 Years and over, 62 participants planned
- Where:
- Canada
Phase 3Ketamine / esketamineNCT05603104
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure (INTENSIFY)
- Conditions:
- Schizophrenia and Related Disorders; Major Depressive Disorder; Bipolar Depression
- Sponsor:
- Dr. Inge Winter
- Who:
- ages 18 Years to 70 Years, 1254 participants planned
- Where:
- Israel
Phase 2LSDNCT05883540
Lysergic Acid Diethylamide (LSD) in Palliative Care (LPC)
- Conditions:
- Palliative Care; Pain; Anxiety; Depression; Demoralization; Psychological Distress; Quality of Life; Caregiver Burden; Fear of Death; Existential Distress
- Sponsor:
- University Hospital, Basel, Switzerland
- Who:
- ages 22 Years and over, 60 participants planned
- Where:
- Switzerland
Phase 3Ketamine / esketamineNCT05973851
The Effect of a Six Week Intensified Pharmacological Treatment for Major Depressive Disorder Compared to Treatment as Usual in Subjects Who Had a First-time Treatment Failure on Their First-line Treatment. (INTENSIFY MDD)
- Conditions:
- Major Depressive Disorder; Treatment Resistant Depression
- Sponsor:
- Dr. Inge Winter
- Who:
- ages 18 Years to 65 Years, 418 participants planned
- Where:
- Austria, Germany, Greece, Italy, Spain, United Kingdom
Phase 2PsilocybinNCT06072898
A Randomized Neuroimaging Trial of Psilocybin in Depression (EMBRACE)
- Conditions:
- Depressive Disorder; Major Depressive Disorder
- Sponsor:
- Sunnybrook Health Sciences Centre
- Who:
- ages 18 Years to 64 Years, 50 participants planned
- Where:
- Canada
Phase 1/2Ketamine / esketamineNCT06090422
Ketamine for Combined Depression and Alcohol Use Disorder (KeDA)
- Conditions:
- Depression; Alcohol Use Disorder
- Sponsor:
- University Hospital of North Norway
- Who:
- ages 18 Years to 65 Years, 34 participants planned
- Where:
- Norway
Phase 4Ketamine / esketamineNCT06103760
Positioning of Esketamine Treatment in the Real-world Management of Depression (PoET)
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Royal North Shore Hospital
- Who:
- ages 18 Years to 65 Years, 162 participants planned
- Where:
- Australia
Phase 4Ketamine / esketamineNCT06278779
Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (TREK)
- Conditions:
- Treatment Resistant Depression
- Sponsor:
- The George Institute
- Who:
- ages 18 Years and over, 162 participants planned
- Where:
- Australia
Phase 2PsilocybinNCT06319378
Cancer Related Major Depression Treated With a Single Dose of Psilocybin (CAPSI)
- Conditions:
- MDD
- Sponsor:
- Section for Affective Disorders; Northern Stockholm Psychiatry
- Who:
- ages 20 Years to 80 Years, 100 participants planned
- Where:
- Sweden
Phase 2PsilocybinNCT06378229
Psilocybin for Hospitalized Patients with Treatment-resistant Depression (PSIHOS-D)
- Conditions:
- Treatment Resistant Depression
- Sponsor:
- University Hospital, Ghent
- Who:
- ages 18 Years and over, 100 participants planned
- Where:
- Belgium
Phase 2Ketamine / esketamineNCT06410599
Pharmacologic Treatment Augmentation in Chronic Depression (Ket+CBASP)
- Conditions:
- Major Depressive Disorder
- Sponsor:
- University Hospital Tuebingen
- Who:
- ages 18 Years to 64 Years, 60 participants planned
- Where:
- Germany
Phase 3Ketamine / esketamineNCT06508710
Early Effects of Ketamine vs Placebo With Venlafaxine in Severe Depression Patients (MOODBOOSTER)
- Conditions:
- Major Depressive Episode
- Sponsor:
- Assistance Publique - Hôpitaux de Paris
- Who:
- ages 18 Years to 65 Years, 60 participants planned
- Where:
- France
Phase 2PsilocybinNCT06512220
Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) (SYNVEST)
- Conditions:
- Treatment Resistant Depression
- Sponsor:
- Centre for Addiction and Mental Health
- Who:
- ages 18 Years to 65 Years, 12 participants planned
- Where:
- Canada
Phase 2PsilocybinNCT06518720
Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND) (TRANSCEND)
- Conditions:
- Treatment Resistant Depression; Chronic Pain
- Sponsor:
- Centre for Addiction and Mental Health
- Who:
- ages 18 Years to 65 Years, 16 participants planned
- Where:
- Canada
Phase not statedKetamine / esketamineNCT06620276
ACT_for Alcohol Use Disorder and Depression
- Conditions:
- Depression - Major Depressive Disorder; Alcohol Use Disorder
- Sponsor:
- Centre hospitalier de l'Université de Montréal (CHUM)
- Who:
- ages 18 Years to 70 Years, 30 participants planned
- Where:
- Canada
Phase 3Ketamine / esketamineNCT06781697
InTRavenous kEtAmine and immerSive virtUal Reality to Treat dEpression (TREASURE)
- Conditions:
- Treatment Resistant Depression
- Sponsor:
- Sunnybrook Health Sciences Centre
- Who:
- ages 18 Years and over, 31 participants planned
- Where:
- Canada
Phase 2PsilocybinNCT06782724
Psilocybin Therapy for Psychological Distress in Palliative Patients (PsyPal)
- Conditions:
- COPD (Chronic Obstructive Pulmonary Disease); ALS (Amyotrophic Lateral Sclerosis); MS (Multiple Sclerosis); Major Depressive Disorder (MDD); Atypical Parkinson Disease
- Sponsor:
- University Medical Center Groningen
- Who:
- ages 18 Years and over, 108 participants planned
- Where:
- Czechia, Denmark, Netherlands, Portugal
Early phase 1Ketamine / esketamineNCT06784388
Personalized DBS Targeting for Treating Depression
- Conditions:
- Treatment-resistant Depression (TRD)
- Sponsor:
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Who:
- ages 18 Years to 70 Years, 5 participants planned
- Where:
- China
Phase 2/3Ketamine / esketamineNCT06891300
Understanding and Treating Suicidal Ideation With Ketamine
- Conditions:
- Suicidal Ideation; Major Depressive Disorder (MDD)
- Sponsor:
- The Royal's Institute of Mental Health Research
- Who:
- ages 18 Years to 65 Years, 36 participants planned
- Where:
- Canada
Phase 1/2PsilocybinNCT06898606
Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression (COGUNILA)
- Conditions:
- Depressive Disorder
- Sponsor:
- Federal University of Latin American Integration
- Who:
- ages 25 Years to 65 Years, 24 participants planned, accepts healthy volunteers
- Where:
- Brazil
Phase not statedDMT / ayahuascaNCT06927076
Antidepressant Response of DMT Masked With Propofol (DMT4D)
- Conditions:
- Major Depressive Disorder; Psychedelic Experiences
- Sponsor:
- University Hospital, Basel, Switzerland
- Who:
- ages 21 Years and over, 112 participants planned
- Where:
- Switzerland
Phase 2PsilocybinNCT06943573
Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder (PAT-BD-01)
- Conditions:
- Bipolar II Depression
- Sponsor:
- Lakshmi N Yatham
- Who:
- ages 19 Years to 65 Years, 90 participants planned
- Where:
- Canada
ObservationalKetamine / esketamineNCT07002684
Metabolic Profiling of Esketamine Treatment in Depressive Disorder
- Conditions:
- Major Depressive Disorder
- Sponsor:
- University of Zagreb
- Who:
- ages 18 Years to 70 Years, 100 participants planned, accepts healthy volunteers
- Where:
- Croatia
Phase 3Ketamine / esketamineNCT07088380
Ketamine Augmentation of ECT in Treatment-Resistant Depression (Ketamina)
- Conditions:
- Major Depressive Disorder; Treatment Resistant Depression
- Sponsor:
- Università Vita-Salute San Raffaele
- Who:
- ages 18 Years to 70 Years, 30 participants planned
- Where:
- Italy
ObservationalKetamine / esketamineNCT07146503
Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression (ESKPSY)
- Conditions:
- Depression and Quality of Life; Treatment Resistant Depression (TRD); Anhedonia; Apathy; Anxiety; Cognition; Temperament; Psychiatric Comorbidities
- Sponsor:
- Riccardo Guglielmo
- Who:
- ages 18 Years to 74 Years, 100 participants planned
- Where:
- Italy
Phase 2PsilocybinNCT07183748
Psilocybin Microdosing With Psychotherapy for Treatment-Resistant Depression
- Conditions:
- Treatment Resistant Depression
- Sponsor:
- Beersheva Mental Health Center
- Who:
- ages 18 Years to 65 Years, 20 participants planned
- Where:
- Israel
Phase 2PsilocybinNCT07210112
Efficacy of Psilocybin and Trazodone Combination in Treatment-resistant Depression: a Randomized Controlled Proof-of-concept Study (PSILOTRAZ) (PSILOTRAZ)
- Conditions:
- Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD)
- Sponsor:
- Centre Hospitalier St Anne
- Who:
- ages 18 Years and over, 112 participants planned
- Where:
- France
Phase 2PsilocybinNCT07211438
Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression (PSI-TNT)
- Conditions:
- Treatment-Resistant Depression
- Sponsor:
- Centre for Addiction and Mental Health
- Who:
- ages 18 Years to 70 Years, 40 participants planned
- Where:
- Canada
Early phase 1Ketamine / esketamineNCT07247968
Subanesthetic Esketamine in Modified ECT for Severe Depression in Adolescents: Clinical and Mechanistic Study
- Conditions:
- Esketamine; ECT; Depression; Adolescent
- Sponsor:
- Min Su
- Who:
- ages 13 Years to 17 Years, 220 participants planned
- Where:
- China
Phase 4Ketamine / esketamineNCT07369102
Esketamine With or Without Integration Therapy for Treatment-Resistant Depression (KIND-PR)
- Conditions:
- Treatment-resistant Depression (TRD)
- Sponsor:
- University of Puerto Rico
- Who:
- ages 21 Years to 65 Years, 20 participants planned
- Where:
- Puerto Rico
Phase 2PsilocybinNCT07405606
Psilocybin-assisted Therapy for Comorbid Major Depressive Disorder and Alcohol Use Disorder
- Conditions:
- Major Depressive Disorder (MDD); Alcohol Use Disorder (AUD)
- Sponsor:
- Centre for Addiction and Mental Health
- Who:
- ages 18 Years to 65 Years, 30 participants planned
- Where:
- Canada
Phase not statedKetamine / esketamineNCT07422519
Virtual Reality-Based Mindfulness as an Adjunct to Treatment as Usual in Treatment-Resistant Depression
- Conditions:
- Depression - Major Depressive Disorder; Depression Disorder; Depression Chronic; Treatment-Resistant Major Depressive Disorder
- Sponsor:
- Hospital Universitari Vall d'Hebron Research Institute
- Who:
- ages 18 Years to 74 Years, 30 participants planned
- Where:
- Spain
Phase 1PsilocybinNCT07490353
Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects
- Conditions:
- Depression - Major Depressive Disorder; Anhedonia
- Sponsor:
- Medical University of Vienna
- Who:
- ages 18 Years to 55 Years, 85 participants planned, accepts healthy volunteers
- Where:
- Austria
Phase 2DMT / ayahuascaNCT07562191
Inhaled DMT for Major Depressive Disorder (DMT-MDD)
- Conditions:
- MDD; Major Depressive Disorder (MDD); Major Depression; Suicidal Ideation; Suicide
- Sponsor:
- Universidade Federal do Rio Grande do Norte
- Who:
- ages 18 Years and over, 140 participants planned
- Where:
- Brazil
Phase 2Ketamine / esketamineNCT07569198
Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) (KET-DBT)
- Conditions:
- Borderline Personality Disorder (BPD); Treatment-Resistant Major Depressive Disorder; Treatment-resistant Bipolar Depression; Major Depressive Disorder (MDD); Bipolar Disorder (BD); Bipolar Disorder I or II; Suicidal Ideation
- Sponsor:
- Joshua Rosenblat
- Who:
- ages 18 Years to 70 Years, 120 participants planned
- Where:
- Canada
Phase 3PsilocybinNCT07638553
Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms (ERPPAD)
- Conditions:
- Alcohol Use Disorder; Depressive Sympotoms; Psilocybin
- Sponsor:
- Centre Hospitalier Universitaire de Nīmes
- Who:
- ages 18 Years and over, 172 participants planned
- Where:
- France
Phase 3PsilocybinNCT07703722
Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder
- Conditions:
- Major Depressive Disorder; Post-Traumatic Stress Disorder (PTSD)
- Sponsor:
- Khyber Medical University Peshawar
- Who:
- ages 18 Years to 60 Years, 60 participants planned
- Where:
- Pakistan